Aeglea BioTherapeutics, Inc. — FY2020 Form 10-K Summary
Filing identity: The supplied filing is for Aeglea BioTherapeutics, Inc. (Nasdaq: AGLE), not Spyre Therapeutics, Inc. It reports the fiscal year ended December 31, 2020 and was filed March 18, 2021. The filing does not identify the company as Spyre Therapeutics.
Business context and reporting period
Aeglea was a clinical-stage biotechnology company developing engineered human enzyme therapeutics for rare metabolic diseases. Its lead programs were pegzilarginase for Arginase 1 Deficiency and AGLE-177 for Homocystinuria. The company also maintained preclinical programs for Cystinuria and other metabolic diseases. Aeglea had 90 employees as of December 31, 2020 and operated as a single reporting segment.
- Pegzilarginase was being evaluated in the global Phase 3 PEACE trial and an open-label extension study.
- AGLE-177 entered a Phase 1/2 trial, but first-patient dosing remained pending because of COVID-19-related site restrictions.
- The company had no approved products and generated no product revenue.
Financial performance and liquidity
| Metric | 2020 | 2019 | Change |
|---|---|---|---|
| Revenue | $0 | $0 | No change |
| Research and development expense | $59.6 million | $64.6 million | Down 8% |
| General and administrative expense | $21.8 million | $15.7 million | Up 39% |
| Total operating expenses | $81.5 million | $80.3 million | Up 1% |
| Operating loss | $81.5 million | $80.3 million | Loss increased $1.1 million |
| Net loss | $80.9 million | $78.3 million | Loss increased $2.6 million |
| Net loss per share | $1.52 | $2.45 | Improved due primarily to share issuance |
| Operating cash flow | $(75.8) million | $(65.7) million | Cash use increased $10.1 million |
| Capital expenditures | $4.3 million | $1.5 million | Increased |
The company had an accumulated deficit of $276.0 million at year-end. Cash, cash equivalents, marketable securities and restricted cash totaled $148.1 million, including $90.1 million of cash and cash equivalents, $56.2 million of marketable securities and $1.8 million of restricted cash. Working capital was $133.3 million.
Aeglea reported no debt or credit facility. Total liabilities were $21.8 million, consisting primarily of accounts payable, accrued liabilities and lease obligations. Contractual lease obligations totaled $8.2 million for operating leases and $0.1 million for finance leases.
Financing activities provided $154.5 million in 2020. The company raised $129.0 million net from an underwritten offering and $24.6 million net through an at-the-market offering. Management stated that available resources were expected to fund operations into 2023, but also disclosed that additional financing would be required to complete all planned development activities.
Material changes versus the prior comparable period
- Research and development expense declined by $5.0 million, primarily because certain pegzilarginase, oncology and toxicology activities were completed; this was partly offset by higher personnel costs and increased AGLE-177 manufacturing activity.
- General and administrative expense increased by $6.1 million due to commercial-team expansion, professional and legal services, and additional facilities.
- Operating cash use increased from $65.7 million to $75.8 million.
- Interest income declined from $2.1 million to $0.6 million because of lower investment yields.
- Common shares outstanding increased from 29.1 million at year-end 2019 to 48.0 million at year-end 2020, excluding the potential dilution from 17.6 million outstanding pre-funded warrants.
- Total assets increased from $83.2 million to $161.6 million, primarily reflecting equity financing proceeds.
Guidance, outlook, risks and unusual items
- Management expected PEACE enrollment to close in March 2021, completion of screening and randomization by the end of April 2021, and topline data in the fourth quarter of 2021.
- COVID-19 caused temporary suspension of trial-site screening, missed dosing appointments, slower enrollment, and delays to AGLE-177 dosing. Further disruptions to clinical operations, manufacturing, supply chains and regulatory review remained possible.
- Pegzilarginase had FDA and EMA Orphan Drug Designation, FDA Fast Track and Breakthrough Therapy Designations, and FDA Rare Pediatric Disease designation. These designations did not assure approval or commercial success.
- The primary PEACE endpoint was plasma arginine reduction; regulators could require convincing improvements in clinically meaningful outcomes in addition to biomarker results.
- The company relied on contract research organizations and third-party manufacturers, including Fujifilm Diosynth, with limited manufacturing redundancy.
- Aeglea had no product revenue, expected continuing losses and required substantial additional capital. Future equity financing could dilute existing shareholders.
- Key risks included clinical-trial failure, patient-enrollment challenges in rare diseases, adverse events, regulatory uncertainty, manufacturing and supply constraints, intellectual-property challenges, reimbursement limitations and competition.
- The University of Texas license arrangements could require up to $6.4 million in milestone payments per covered program, plus royalties and sublicense revenue sharing. CPRIT was entitled to royalties on certain future revenues related to grant-funded technology.
- On March 16, 2021, the company granted registration rights to Baker Brothers funds. On the same date, CEO Anthony Quinn was appointed principal financial officer following the CFO’s resignation.
Most important facts for an investor to verify
- Confirm the issuer’s identity: the supplied filing is Aeglea BioTherapeutics, Inc., while the request metadata names Spyre Therapeutics, Inc.
- Verify current clinical status and the results of the Phase 3 PEACE trial, including both plasma arginine reduction and clinical mobility endpoints.
- Assess the company’s cash runway against its stated 2023 funding horizon and expected future financing needs.
- Evaluate dilution from the 2020 offerings, the at-the-market program and 17.6 million outstanding pre-funded warrants.
- Review whether AGLE-177 advanced beyond the COVID-19-related delay in first-patient dosing.
- Review manufacturing capacity, supplier concentration and the ability to produce commercial-scale pegzilarginase.
- Confirm the scope, validity and remaining term of owned and licensed patent protection and associated milestone and royalty obligations.